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Rab25 as a tumour suppressor in colon carcinogenesis
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Recent investigations have increasingly focussed attention on the roles of intracellular vesicle trafficking in the regulation of epithelial
polarity and transformation. Rab25, an epithelial-specific member of the Rab family of small GTPases, has been associated with several
epithelial cancers. Whereas Rab25 overexpression is associated with ovarian cancer aggressive behaviour, Rab25 expression is
decreased in human colon cancers independent of stage. Recent studies of mouse models of intestinal and colonic neoplasia have
demonstrated that Rab25 deficiency markedly promotes the development of neoplasia. Some of these effects appear related to
alterations in b1-integrin trafficking to the cell surface. These findings all suggest that Rab25 is a tumour suppressor for colonic
neoplasia.
British Journal of Cancer (2011) 104, 33–36. doi:10.1038/sj.bjc.6605983 www.bjcancer.com
Published online 9 November 2010
& 2011 Cancer Research UK
Keywords: Rab proteins; colon cancer; vesicle trafficking; Rab11-FIP; integrin; Smad3





































Transformation of cancer cells involves alterations in both cell
shape and behaviour. Intrinsic to the pathophysiology of epithelial
cancers is a loss of polarised epithelial monolayers and adoption of
migratory cell behaviours that lead to locally invasive disease and
metastasis. This transition in cell behaviour during carcinogenesis
requires global changes in cell surface components that maintain
the normal polarised phenotype including junctional proteins,
integrins and plasma membrane receptors, pumps and channels.
Over the past decade, research in a number of cell systems has
revealed that directed trafficking of cell surface proteins is not a
simple matter of protein synthesis and targeting. Rather, the
phenotype of cell surface protein expression reflects a dynamic
interplay of de novo delivery, internalisation, targeted degradation
and recycling (Mellman and Nelson, 2008). At any given moment,
the compendium of cell surface proteins present on normal or
abnormal cells is determined by the net effects of all of these
trafficking processes. It is therefore now increasingly clear that
changes in critical trafficking pathways can induce alterations in
cell surface proteins leading to alterations in polarity and
susceptibility to further steps that may lead to transformation.
The importance of the loss of polarity in the generation of early
neoplasia has received greater scrutiny over the past several years.
The establishment of polarity with segregation of apical and
basolateral membrane domains is perhaps the most obvious
manifestation of polarity. The maintenance of the boundaries
between these polarised membrane regions by components of the
tight and adherens junctions is critical for control of the polarised
epithelial barrier (Mellman and Nelson, 2008). Polarity also sets
up critical functions of ligand movement between polarised
surfaces (transcytosis) as well as polarised transport of ions and
nutrients and polarised signalling through membrane receptors.
The appropriate presentation of proteins and their density at the
polarised surfaces markedly impacts the physiology of the
epithelial monolayer. Loss of junctional components such as
E-cadherin or p120 can lead to loss in epithelial polarity and
eventual derangement of the epithelial monolayer, a precancerous
event (Chen et al, 2003; Balzac et al, 2005; Lioni et al, 2007; Dohn
et al, 2009; Smalley-Freed et al, 2010). As individual alterations of
particular proteins may not be sufficient to alter general epithelial
polarity, multiple derangements are likely required to induce the
level of functional polarity loss necessary as an early step in
carcinogenesis. Multiple hits are then likely to lead to transforma-
tion (loss of contact inhibition), invasion and metastasis.
The Rab proteins comprise the largest family of small GTPases,
with over 60 mammalian gene products (Schwartz et al, 2007). Rab
proteins associate with distinct membrane compartments within
cells and are thought to represent the nidus for the assembly of
multiprotein complexes that determine the specificity of vesicle
trafficking pathways within cells (Somsel Rodman and Wandinger-
Ness, 2000). In particular, the family of Rab11 GTPases, containing
Rab11a, Rab11b and Rab25, is involved in the regulation of
recycling of internalised membrane proteins (Ullrich et al, 1996;
Casanova et al, 1999; Wang et al, 2000) as well as the movement of
membrane proteins between polarised surfaces of epithelial cells
(Jones et al, 2006). Although Rab11a and Rab11b are ubiquitously
expressed, Rab25 is expressed only in epithelial cells (Goldenring
et al, 1993). Rab25 contains an unusual WDTAGLE sequence in its
GTP-binding domain. This sequence mimics the Q to L mutation
seen in Ras and other Rab that confers a loss of GTPase activity
(the dominant active phenotype). However, we have demonstrated
previously that Rab25 retains an active GTPase activity (Casanova
et al, 1999). Although expression of Rab25 is generally low,
overexpression studies in MDCK cells indicated that Rab25 was a
negative regulator of epithelial cell basolateral-to-apical transcy-
tosis (Casanova et al, 1999; Wang et al, 2000). More recently,
investigations by Lencer and colleagues (Tzaban et al, 2009) have
demonstrated that Rab25 regulates apical-to-basolateral transcy-
tosis in polarised MDCK cells. These findings suggest that Rab25 is
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an important regulator of polarised cell surface composition.
Although most previous studies have focussed on investigation of
model trafficking cargoes expressed in MDCK cells (e.g., polymeric
IgA for basolateral-to-apical transcytosis and FcRN for apical-to-
basolateral transcytosis of IgG), the endogenous cargoes for
Rab25-dependent trafficking have remained generally obscure.
All of the Rab11 family members can interact with classes of
Rab11-family interacting proteins (Rab11-FIPs) as well as the
actin-based motors Myosin Va and Myosin Vb (Hales et al, 2001;
Lapierre et al, 2001; Roland et al, 2009). In vitro data indicate that
these proteins can bind to all three Rab11 family members, in the
case of Rab11-FIPs, through a conserved amphipathic a-helix
domain (Hales et al, 2001). Nevertheless, it is not at all clear
whether there are real differences in affinity in vivo. A number of
recent studies have implicated Rab11-family effector proteins in
the regulation of the polarised cell phenotype. Phosphory-
lation of Rab11-FIP2 by Par1b/MARK2 appears to regulate the
establishment of polarity in MDCK cells (Ducharme et al, 2006).
Overexpression of Rab11-FIP2(S227A) inhibits the re-establish-
ment of the polarised monolayer following disruption by calcium
chelation. Loss of functional myosin Vb has also been identified
recently as the key mutation in neonates with microvillous
inclusion disease (MVID) (Erickson et al, 2008; Muller et al,
2008). The intestinal epithelia in MVID patients show a prominent
loss of apical microvilli as well as apical membrane inclusions,
which lead to devastating neonatal diarrhoea (Iancu et al, 2007).
Recent studies have suggested that these losses in apical
differentiation are associated with defects in polarity (Muller
et al, 2008). Thus, alterations in membrane recycling system
functions can lead to remarkable changes in polarised function.
Nevertheless, it is important to note that in the case of MDCK cells
expressing the Rab11-FIP2(S227A) mutation, once the epithelial
polarity is established, the general functional characteristics of the
resistance of the monolayer are essentially normal (Ducharme
et al, 2006). Thus, single defects can be compensated for through
other mechanisms. In addition, whereas defects in the intestinal
epithelia of MVID patients are remarkable, kidney epithelia appear
unaffected. Thus, different epithelial cells may have greater or
lesser abilities to compensate for specific deficits.
A number of recent investigations have implicated Rab proteins
in the process of carcinogenesis (recently reviewed in Chia and
Tang, 2009). A number of studies have implicated the early
endosomal Rab proteins Rab5 and Rab21 in the regulation of
tumour cell behaviour (Pellinen et al, 2006, 2008; Torres et al,
2010). However, specific trafficking defects in recycling system
function have not been studied extensively. It was therefore of
interest in 2004 when Mills and colleagues (Cheng et al, 2004)
noted that regions of chromosome 1 amplification associated with
ovarian cancer were associated with marked increases in the
expression of Rab25. In those investigations, Rab25 overexpression
correlated with the aggressiveness of the cancer. The investigators
also suggested that Rab25 was overexpressed in breast cancers.
Nevertheless, in the past 2 years, it has become clear that Rab25
overexpression in breast cancer is likely less common and that
indeed, at least in oestrogen receptor-deficient cancers, expression
is actually decreased significantly (Cheng et al, 2006, 2010).
We have investigated the role of Rab25 in colon cancer patients
(Nam et al, 2010). In two independent patient cohorts, gene
microarray studies demonstrated that Rab25 expression was
decreased in colon cancers independent of clinical and patholo-
gical staging. Importantly, Rab25 loss was associated with poorer
survival. Interestingly, we did not observe any significant changes
in the expression of Rab11a, Rab11b, any of the Rab11-FIP
proteins or myosin Vb. These results suggested that loss of this
epithelial-specific Rab protein was associated with an increased
susceptibility to colon carcinogenesis.
To address the impact of loss of Rab25 on colon carcinogenesis,
we developed a novel mouse model for genetic deletion of Rab25.
Although we did not observe any effects of Rab25 loss in the
knockout mouse strains themselves, when these mice were crossed
onto mice with established susceptibility to developing intestinal
neoplasms, we observed marked acceleration of tumourigenesis.
In the case of the adenomatous polyposis coli model ApcMin mice,
breeding onto the Rab25 knockout background led to a four-fold
increase in polyp number in the intestines and a two-fold increase
in the tumour number in the colon (Nam et al, 2010). Interestingly,
these polyps retained relatively well-differentiated morphologies of
adenomatous polyps and did not show any increase in invasive
properties. These results supported a concept that Rab25
promoted polyp initiation.
Although the ApcMin mouse is a good model for polyposis
(D’Abaco et al, 1996), it is less suitable to address colon
carcinogenesis. We therefore also examined the influence of
Rab25 loss on colon tumourigenesis in the Smad3 knockout mouse
model (Zhu et al, 1998). Smad3 knockout mice develop colon
tumours by 6 months of age. Heterozygous Smad3þ / mice do
not develop any pathology. We therefore were surprised to find
that 480% of Smad3þ /; Rab25/ mice demonstrated large
invasive colon tumours throughout the colon by 15 weeks of age.
Interestingly, we could still demonstrate, although reduced, Smad3
expression in the tumours, and hence the effects appeared to be
synergistic. Although it is presently not clear what mechanisms
account for the remarkable increase in colon carcinogenesis in this
model, it is important to note that the Smad3þ /; Rab25/ mice
may represent a critical new model for colon carcinogenesis.
Whereas Smad3/ mice show a marked overall deficit in weight
gain throughout life, the Smad3þ /; Rab25/ mice grow similarly
to wild-type mice. The highly invasive, and perhaps locally
metastatic, character of the tumours and their rapid and highly
penetrant phenotype makes this model perhaps the most adaptable
model for the study of colon carcinogenesis in mice. The size of the
tumours developed will likely be amenable to imaging and
endoscopy approaches and could be of high utility in preclinical
studies of novel colon cancer treatments (Deane et al, 2007).
What alterations in Rab25 knockout mice could be responsible
for the increased susceptibility to intestinal and colon neoplasia
when a second deficiency is added (either mutant Apc or reduction
in Smad3)? Norman and colleagues (Caswell et al, 2007) have
previously demonstrated that increases in Rab25 in ovarian cancer
cells were associated with aberrations in the cell surface
localisation of b1-integrin. We therefore evaluated the expression
of b1-integrin in the Rab25-deficient mouse intestine. Whereas in
wild-type mice b1-integrin was strongly expressed in the cells of
the villus, we observed a decrement in basolateral b1-integrin and
an increase in intracellular b1-integrin in the Rab25-deficient mice
(Nam et al, 2010). Interestingly, we also observed the highest
concentrations of Rab25 expression in the cells in the transition
between the crypt and villus regions of the intestinal mucosa. This
is the critical region for the upregulation of b1-integrin expression
in the mucosa and is also the region implicated in the formation of
adenomas in ApcMin mice. Thus, a loss of proper b1-integrin
trafficking to the basolateral membranes during maturation of cells
from the crypt to the villus may provide the predisposing
decrement that, with the addition of Apc loss, could lead to
increased polyp formation. Interestingly, in the case of ApcMin
mice, we also observed that Rab25 heterozygote mice, which
display an intermediate amount of Rab25 expression, showed an
intermediate increase in polyp formation (Nam et al, 2010).
Combined with the results in ovarian cancer cells, it appears that
manipulation of Rab25 levels can lead to aberrations in the
trafficking of b1-integrin and perhaps other critical regulators of
cell adhesion (Figure 1). Nevertheless, although evidence does
exists for the regulation of integrin trafficking in non-polarised
cells by Rab11a (Mitchell et al, 2004), the exact mechanism that
could account for the alterations of integrin trafficking remain
unclear. Norman and colleagues (Caswell et al, 2007) have
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observed that under certain circumstances, some overlap of
internalised b1-integrin and Rab25 can be observed; however, we
have not been able to demonstrate colocalisation of b1-integrin
with Rab25 in intestinal systems. Norman et al (Caswell et al, 2007)
have also shown evidence for a possible direct interaction of Rab25
with b1-integrin. Nevertheless, the effects of Rab25 expression
changes on integrins may also reflect en passant effects because of
either alteration in the trafficking of another cargo (e.g., the EGF
receptor) or perhaps by changing the effective concentration of
direct effectors shared with Rab11a (e.g., Rab11-FIPs; Figure 1).
Alternatively, the alterations seen with loss of Rab25 could reflect
an alteration in the downstream effects mediated by Rab11-FIP1C/
RCP. Although we did not observe any alterations in expression of
Rab11-FIP1C in human colon cancers, recent investigations in
breast cancer have implicated overexpression of Rab11-FIP1C
in breast cancers (Zhang et al, 2009). In addition, these studies
have suggested that Rab11-FIP1C can interact with and regulate
activation of Ras (Figure 1). Similarly, in colon cancers, changes in
Rab25 expression may lead to alterations in Ras through changes
in competition between Rab25 and Ras for Rab11-FIP1C.
Thus, although it is clear that Rab25 can impact epithelial cell
transformation, the exact mechanism remains elusive. It appears
that the effects of Rab25 expression depend largely on context.
Thus, either overexpression or loss of Rab25 expression can lead to
transformation. It seems likely that these findings result from cell-
specific roles for Rab25 in the trafficking of specific cargoes. Thus,
if, as is documented in MDCK cells (Tzaban et al, 2009), Rab25 is
involved in apical-to-basolateral transcytosis, either overexpres-
sion or loss of expression could lead to imbalances in the
distribution of trafficking cargoes between the apical and
basolateral membranes. Imbalances on either end of the spectrum
could lead to loss in polarity that predisposes to transformation.
Similarly, if trafficking outcomes depend on a competition
between Rab25 and Rab11a for Rab11-FIPs (Figure 1), then
overexpression or loss of Rab25 expression could have marked
effects on the flow through membrane recycling systems
of multiple cargoes, including signalling receptors such as the
EGF receptor or TGF-b receptors. In considering these rather
subtle effects, it is important to note that small defects in the
efficiency of dynamic trafficking over an extended period of time
may lead to progressive deficits, perhaps contributing to the
age-related increase in cancer incidence.
CONCLUSION
Loss of Rab25 in human colon cancers is associated with
poorer patient prognosis. Although Rab25-deficient mice do not
develop spontaneous colon tumours, breeding of ApcMin mice onto
the Rab25-deficient background induces a marked increase in
tumours, and crossing of Smad3þ / mice onto the Rab25
knockout background yields large invasive tumours. These results
indicate that Rab25 is an important tumour suppressor in the
colon. Given the results in both ovarian and breast cancer studies,
it is likely that Rab25 influences the trafficking and recycling of a
number of key regulators of polarity and signalling involved in
transformation. Thus, either loss of Rab25 or overexpression of
Rab25 may lead to cell transformation based on the cell-specific
alteration in surface protein delivery.
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